###begin article-title 0
Lack of association between the chemokine receptor 5 polymorphism CCR5delta32 in rheumatoid arthritis and juvenile idiopathic arthritis
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 114 119 114 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCR5 </italic>
###xml 195 207 195 203 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCR5&#916;32 </italic>
###xml 431 443 427 435 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCR5&#916;32 </italic>
The chemokine receptor CCR5 has been detected at elevated levels on synovial T cells, and a 32 bp deletion in the CCR5 gene leads to a non-functional receptor. A negative association between the CCR5Delta32 and rheumatoid arthritis (RA) has been reported, although with conflicting results. In juvenile idiopathic arthritis (JIA), an association with CCR5 was recently reported. The purpose of this study was to investigate if the CCR5Delta32 polymorphism is associated with RA or JIA in Norwegian cohorts.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 74 86 74 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCR5&#916;32 </italic>
###xml 7 15 <span type="species:ncbi:9606">patients</span>
###xml 25 33 <span type="species:ncbi:9606">patients</span>
853 RA patients, 524 JIA patients and 658 controls were genotyped for the CCR5Delta32 polymorphism.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 4 16 4 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCR5&#916;32 </italic>
###xml 96 98 92 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 143 145 139 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 197 208 193 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCR5&#916;32</italic>
###xml 75 83 <span type="species:ncbi:9606">patients</span>
###xml 122 130 <span type="species:ncbi:9606">patients</span>
The CCR5Delta32 allele frequency was 11.5% in the controls vs. 10.4% in RA patients (OR = 0.90; P = 0.36) and 9.7% in JIA patients (OR = 0.85; P = 0.20). No decreased homozygosity was observed for CCR5Delta32, as previously suggested.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 51 63 51 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCR5&#916;32 </italic>
###xml 215 227 211 219 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCR5&#916;32 </italic>
###xml 94 102 <span type="species:ncbi:9606">patients</span>
Our data do not support an association between the CCR5Delta32 allele and Norwegian RA or JIA patients. Combining our results with those from a recently published meta-analysis still provide evidence for a role for CCR5Delta32 in RA, albeit substantially weaker than the effect first reported.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 217 218 217 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 219 220 219 220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 566 567 559 560 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 635 636 628 629 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 647 648 640 641 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 729 730 722 723 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 739 740 732 733 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 710 718 <span type="species:ncbi:9606">patients</span>
In rheumatoid arthritis (RA) and juvenile idiopatic arthritis (JIA), the synovium is infiltrated with T cells and macrophages, and chemokine receptors and their ligands are involved in regulation of the inflammation [1,2]. Chemokines regulate lymphocyte trafficking by inducing cell motility and activating adhesion molecules. The chemokine receptor CCR5 is a G-protein-coupled seven-transmembrane-receptor, and it is expressed on monocytes, macrophages, memory T-cells and dendritic cells, where it serves as a receptor for RANTES, MIP-1-alpha, MIP-1-beta and MCP [3]. CCR5 has functionally been implicated in the pathogenesis of RA [2] and JIA [4]. The expression of CCR5 is increased on synovial T cells in patients with JIA [4] or RA [5].
###end p 11
###begin p 12
###xml 55 56 55 56 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 84 95 84 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCR5&#916;32</italic>
###xml 104 109 100 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCR5 </italic>
###xml 185 197 181 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCR5&#916;32 </italic>
###xml 255 256 247 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 344 356 336 344 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCR5&#916;32 </italic>
###xml 479 480 467 468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 487 492 475 480 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCR5 </italic>
###xml 563 564 551 552 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 296 301 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 406 411 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The gene encoding CCR5 is located on chomosome 3p21.3 [6]. A 32 base pair deletion (CCR5Delta32) in the CCR5 gene leads to a frame shift and a non-functional receptor. Homozygosity for CCR5Delta32 results in a complete lack of surface expression of CCR5 [7]. CCR5 happens to be a co-receptor for HIV-1 on CD4+ T-cells with the consequence that CCR5Delta32 homozygotes are protected against infections with HIV-1, while heterozygotes have a delay in the progression towards AIDS [8]. The CCR5 deletion is common among Caucasians, especially in Nordic populations [9], but has not been found in native Africans, American Indians or East Indian ethnic groups.
###end p 12
###begin p 13
###xml 12 24 12 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCR5&#916;32 </italic>
###xml 183 185 179 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 186 188 182 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 285 287 281 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 360 372 356 364 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCR5&#916;32 </italic>
###xml 493 495 485 487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 600 612 592 600 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCR5&#916;32 </italic>
###xml 671 673 659 661 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 745 757 733 741 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCR5&#916;32 </italic>
###xml 996 998 980 982 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 430 438 <span type="species:ncbi:9606">patients</span>
###xml 538 546 <span type="species:ncbi:9606">patients</span>
###xml 794 802 <span type="species:ncbi:9606">patients</span>
The role of CCR5Delta32 has been investigated genetically in several immune-mediated diseases. In RA, a negative association of the deletion has been reported with divergent results [10-14], while in childhood arthritis a weak negative association has been observed in a single study [15]. Regarding clinical outcome, it has been reported that carriers of the CCR5Delta32 allele occurred at a significantly higher frequency among patients with non-severe compared to severe disease (N = 160) [14], whereas a later and larger study of 438 patients did not find any association between carriage of the CCR5Delta32 and milder disease severity in inflammatory polyarthritis [16]. A recent meta-analysis of five reports addressing the association of CCR5Delta32 with susceptibility to develop RA in patients of European ancestry (1790 cases and 2717 controls), reported a significant negative association and estimated the deletion to provide disease resistance with an OR = 0.65 (95% CI [0.55-0.77])[17].
###end p 13
###begin p 14
###xml 75 87 75 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCR5&#916;32 </italic>
###xml 175 187 171 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCR5&#916;32 </italic>
The aim of our study was to investigate if there is an association between CCR5Delta32 and RA in the largest individual data set studied so far, as well as to address whether CCR5Delta32 is also associated with JIA, not yet extensively investigated.
###end p 14
###begin title 15
Methods
###end title 15
###begin p 16
###xml 241 243 241 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 477 479 477 479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 7 15 <span type="species:ncbi:9606">patients</span>
###xml 25 33 <span type="species:ncbi:9606">patients</span>
###xml 86 94 <span type="species:ncbi:9606">patients</span>
###xml 257 265 <span type="species:ncbi:9606">patients</span>
###xml 562 570 <span type="species:ncbi:9606">patients</span>
###xml 685 697 <span type="species:ncbi:9606">participants</span>
853 RA patients, 524 JIA patients and 658 controls were included in the study. The RA patients, admitted to the Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, fulfilled the American College of Rheumatology (ACR) criteria [18] and the JIA patients, admitted to the Department of Rheumatology, Rikshospitalet-Radiumhospitalet Medical Center, Oslo, Norway, were classified according to the ILAR (International League of Associations for Rheumatology) criteria [19]. The control group was recruited through the Norwegian Bone Marrow Registry. All patients and controls were of Norwegian origin. The study was approved by the Norwegian Regional Ethics committee, and the participants had given their informed consent.
###end p 16
###begin p 17
###xml 75 79 75 77 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 904 906 884 886 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
Whole-genome amplification was performed on genomic DNA using the Genomiphi(R) kit (GE healthcare systems, Chalfont St. Giles, UK). Amplification of fragment surrounding the deletion was performed with the dye labelled forward primer 5'-ATCACTTGGGTGGTGGCTGTGTTTGCGTCTC and the reverse primer 5'-AGTAGCAGATGACCATGACAAGCAGCGGCAG under the following conditions; denaturation at 94degreesC for 15 seconds, annealing and extension at 70degreesC for 15 seconds, 30 cycles and final extension at 70degreesC for 5 min at a Perkin Elmer 9700 thermal cycler (Applied Biosystems, Foster City, CA, USA). Fragment length was determined on an ABI3730 DNA Analyzer (Applied Biosystems) with subsequent allele calling in GeneMapper v3.7 where a 193 bp PCR product corresponded to the wild type allele and a 161 bp product represented the deletion. Part of the control material was genotyped in our previous publication [20].
###end p 17
###begin p 18
###xml 83 85 83 85 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 126 138 126 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCR5&#916;32 </italic>
###xml 193 195 189 191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 328 336 <span type="species:ncbi:9606">patients</span>
Statistical power was calculated prior to the study using the power calculator at [21], assuming the frequency of 10% for the CCR5Delta32 and an Odds Ratio of 0.56 (obtained from Zapico et al [14]). The power (at alpha = 0.05) was calculated to be 84% for the RA and 75% for the JIA data set. Allele and genotype frequencies in patients and controls were compared by the Chi-Square test, or Fischer's exact test when appropriate, using the Public Domain Software for Epidemiology and Disease Surveillance EPI Info Version 5 (Center of Disease Control, Epidemiology Program Office, Atlanta, GA, USA).
###end p 18
###begin title 19
Results and Discussion
###end title 19
###begin p 20
###xml 39 51 39 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCR5&#916;32 </italic>
###xml 75 76 71 72 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 313 314 305 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 691 693 679 681 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 776 778 764 766 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 822 832 810 820 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p = 0.0068</italic>
###xml 128 136 <span type="species:ncbi:9606">patients</span>
###xml 383 391 <span type="species:ncbi:9606">patients</span>
###xml 492 500 <span type="species:ncbi:9606">patients</span>
The genotype and allele frequencies of CCR5Delta32 are summarised in Table 1. The genotyping success rate was >95% for both the patients and control populations, and all groups were in Hardy-Weinberg equilibrium. No significant negative association was observed with the Delta32 allele in either RA or JIA (Table 1), and only a negligible deviation in frequency was seen between the patients and controls. Furthermore, no decreased frequency for homozygosity of Delta32 was evident among the patients (0.9% in RA, 0.6% in JIA and 1.0% in controls). A revised meta-analysis, calculated by adding our results to those from the recently published meta-analysis of pooled RA cases and controls [17], reduced the initial published risk estimate from OR = 0.65; 95% CI [0.55-0.77], p < 0.0001, to OR = 0.83; 95% CI [0.73-0.95], p = 0.0068.
###end p 20
###begin p 21
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCR5 </italic>
###xml 56 64 <span type="species:ncbi:9606">patients</span>
###xml 73 81 <span type="species:ncbi:9606">patients</span>
CCR5 genotype and allele frequencies among controls, RA patients and JIA patients
###end p 21
###begin p 22
RA: rheumatoid arthritis; JIA: juvenile idiopathic arthritis; N: number of individuals/chromosomes with the denoted genotype/allele; OR (95% CI): Odds ratio with corresponding 95% confidence interval; wt: wild type; Delta32: 32 bp deletion.
###end p 22
###begin p 23
###xml 150 162 150 158 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCR5&#916;32 </italic>
###xml 336 348 332 340 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCR5&#916;32 </italic>
###xml 505 507 497 499 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 510 522 502 510 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCR5&#916;32 </italic>
###xml 594 595 582 583 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 829 835 817 823 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PADI4 </italic>
###xml 836 838 824 826 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 839 841 827 829 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 43 51 <span type="species:ncbi:9606">patients</span>
Our results, from the largest cohort of RA patients and controls investigated to date, do not support the existence of a negative association between CCR5Delta32 and disease (OR = 0.90; 95% CI [0.71-1.14]). Neither was the proposed disease resistance provided by homozygosity of the deletion sustained in our data set. The frequency of CCR5Delta32 in our control population is in the same range as that observed in other European populations and is highly similar to that reported in a Danish population [11]. CCR5Delta32 has been found to have its highest prevalence among Nordic populations [9], which from a statistical power perspective should favour detection of a negative association in our Norwegian cohort, on the other hand deviating results between populations for disease associated alleles is not uncommon, e.g. for PADI4 [22-25].
###end p 23
###begin p 24
###xml 55 67 55 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCR5&#916;32 </italic>
###xml 75 77 71 73 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 78 80 74 76 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 104 106 100 102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 107 109 103 105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 364 376 360 368 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCR5&#916;32 </italic>
###xml 568 572 560 564 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCR5</italic>
###xml 1083 1085 1075 1077 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 1171 1183 1163 1171 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCR5&#916;32 </italic>
###xml 1221 1223 1209 1211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 1422 1424 1410 1412 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 1693 1705 1681 1689 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCR5&#916;32 </italic>
###xml 1868 1870 1852 1854 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 211 219 <span type="species:ncbi:9606">patients</span>
###xml 323 331 <span type="species:ncbi:9606">patients</span>
###xml 829 837 <span type="species:ncbi:9606">patients</span>
###xml 909 917 <span type="species:ncbi:9606">patients</span>
Altogether, two studies suggest an association between CCR5Delta32 and RA [13,14], while three studies [10-12], in addition to ours, do not reveal statistical significant evidence to support this. The number of patients included in the positive studies was 160 and 516 whereas in the negative studies 278, 163, 673 and 853 patients were analysed. A weak effect of CCR5Delta32 on the disease risk, combined with inadequate power, could explain the contradictory results. Alternatively, there could be true differences between the populations in the effect exercised by CCR5; i.e. due to genetic or allelic heterogeneity, variable influence of environmental factors, gene-gene interaction, or variable linkage disequilibrium patterns. All studies display a deviation in the direction of a lower frequency for the deletion among RA patients, but in our data set only a 0.9% reduction in frequency was seen in RA patients compared to controls. The results of a recent meta-analysis of pooled cases and controls were in favour of a negative association (OR = 0.65 (95% CI [0.55-0.77])). [17]. We recalculated the power of our RA study post hoc based on the odds ratio for the CCR5Delta32 obtained in the recent meta-analysis [17], and given this risk effect our power was reduced to 63%. When our RA data set was included in a revised meta-analysis, the overall risk estimate was greatly reduced (OR = 0.83; 95% CI [0.73-0.95, p = 0.0068]). Furthermore, if the true risk estimate is in the range of that calculated after also including our data into the pooled meta-analysis, one would need almost 4000 cases and an equal amount of controls to replicate the finding with an 80% power. Notably, the CCR5Delta32 meta-analysis may also have been prone to type 1 error caused by e.g. publication bias or heterogeneity between the populations included in the combined analysis [26].
###end p 24
###begin p 25
###xml 111 116 111 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCR5 </italic>
###xml 194 206 194 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCR5&#916;32 </italic>
###xml 321 323 317 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 586 588 582 584 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 662 664 658 660 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 806 818 802 810 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCR5&#916;32 </italic>
###xml 476 484 <span type="species:ncbi:9606">patients</span>
Our data does not reveal an association in JIA. After the initiation of our study, the possible association of CCR5 in JIA was addressed, and the authors reported a negative association between CCR5Delta32 and childhood arthritis, particularly in the early onset group and in those diagnosed with pauciarticular subtype [15]. This finding was not sustained in our data set as no association was revealed when stratifying for either JIA subgroups, including the oligoarthirits patients (comparable to the pauciarticular group defined by the ACR criterias; OR = 0.80, 95% CI [0.54-1.17], p = 0.23), or early disease onset (<6 years; OR = 0.81, 95% CI [0.55-1.19], p = 0.27). Further investigations are warranted for JIA before any firm conclusions can be drawn. Nevertheless, our study does not suggest that CCR5Delta32 influences the risk of JIA, and if present the effect is likely to be small.
###end p 25
###begin p 26
###xml 85 90 85 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCR5 </italic>
###xml 453 455 449 451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 484 489 480 485 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCR5 </italic>
###xml 636 648 632 640 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCR5&#916;32 </italic>
###xml 806 811 798 803 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCR5 </italic>
CCR5 has functionally been implicated in RA, and our study does not formally exclude CCR5 as a candidate gene for RA and JIA. Polymorphisms located elsewhere in the gene could potentially be predisposing, and if the associations observed for Delta32 is only secondary due to linkage disequilibrium, that could be an explanation for the discrepant results obtained by different studies. Interestingly, in the recently reported childhood arthritis study [15] other polymorphisms in the CCR5 gene were also investigated, and an additional association with the CCR5 -1835T allele was also observed. No strong linkage disequilibrium between CCR5Delta32 and -1835T was evident, but the haplotype lacking both these alleles displayed positive association, which could suggest that the true etiological variant of CCR5 in RA or JIA pathogenesis that is still unidentified.
###end p 26
###begin title 27
Conclusion
###end title 27
###begin p 28
###xml 27 32 27 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCR5 </italic>
###xml 170 177 170 173 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#916;32</italic>
###xml 263 265 259 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
In conclusion, whether the CCR5 gene is involved in RA or JIA susceptibility remains unclear, however, our study suggests that if a protective effect is exercised by CCR5Delta32, it is minor and less than predicted from the meta-analysis of previous publications[17].
###end p 28
###begin title 29
Competing interests
###end title 29
###begin p 30
The author(s) declare that they have no competing interests.
###end p 30
###begin title 31
Authors' contributions
###end title 31
###begin p 32
###xml 317 325 <span type="species:ncbi:9606">patients</span>
###xml 396 404 <span type="species:ncbi:9606">patients</span>
EL and GBNN participated in the design of the study, performed the genotyping, statistical analysis and drafted the manuscript. EM participated in the design of the study and performed the genotyping of a part of the control material. BF, AMS and OTF contributed with DNA samples and clinical information for the JIA patients. TKK contributed with DNA samples and clinical information for the RA patients. ET helped writing the manuscript. BAL participated in the design of the study, statistical analysis and drafted the manuscript. All authors have read and approved the final manuscript.
###end p 32
###begin title 33
Pre-publication history
###end title 33
###begin p 34
The pre-publication history for this paper can be accessed here:
###end p 34
###begin p 35

###end p 35
###begin title 36
Acknowledgements
###end title 36
###begin p 37
###xml 97 102 <span type="species:ncbi:9606">Women</span>
This work was funded by Rikshospitalet, Southern Norway Regional Health Authority, The Norwegian Women's Health Association and the Norwegian Foundation for Health and Rehabilitation. We thank the Norwegian Bone Marrow Donor Registry for making the control material available and Tom H. Karlsen for valuable input to the study.
###end p 37
###begin article-title 38
Expression of the inflammatory chemokines CCL5, CCL3 and CXCL10 in juvenile idiopathic arthritis, and demonstration of CCL5 production by an atypical subset of CD8+ T cells
###end article-title 38
###begin article-title 39
Chemokines and chemokine receptors in rheumatoid arthritis
###end article-title 39
###begin article-title 40
###xml 78 83 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Interaction of chemokine receptor CCR5 with its ligands: multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding
###end article-title 40
###begin article-title 41
###xml 95 103 <span type="species:ncbi:9606">children</span>
Selective recruitment of polarized T cells expressing CCR5 and CXCR3 to the inflamed joints of children with juvenile idiopathic arthritis
###end article-title 41
###begin article-title 42
Selective accumulation of CCR5+ T lymphocytes into inflamed joints of rheumatoid arthritis
###end article-title 42
###begin article-title 43
###xml 23 28 <span type="species:ncbi:9606">human</span>
The genes encoding the human CC-chemokine receptors CC-CKR1 to CC-CKR5 (CMKBR1-CMKBR5) are clustered in the p21.3-p24 region of chromosome 3
###end article-title 43
###begin article-title 44
Reduced cell surface expression of CCR5 in CCR5Delta 32 heterozygotes is mediated by gene dosage, rather than by receptor sequestration
###end article-title 44
###begin article-title 45
###xml 55 60 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Mechanism of transdominant inhibition of CCR5-mediated HIV-1 infection by ccr5delta32
###end article-title 45
###begin article-title 46
Distribution of the CCR5 gene 32-basepair deletion in West Europe. A hypothesis about the possible dispersion of the mutation by the Vikings in historical times
###end article-title 46
###begin article-title 47
The delta32 deletion of CCR5 receptor in rheumatoid arthritis
###end article-title 47
###begin article-title 48
CC chemokine receptor 5 polymorphism in rheumatoid arthritis
###end article-title 48
###begin article-title 49
Association of rheumatoid arthritis with a functional chemokine receptor, CCR5
###end article-title 49
###begin article-title 50
Evidence for negative association of the chemokine receptor CCR5 d32 polymorphism with rheumatoid arthritis
###end article-title 50
###begin article-title 51
CCR5 (chemokine receptor-5) DNA-polymorphism influences the severity of rheumatoid arthritis
###end article-title 51
###begin article-title 52
Association of two functional polymorphisms in the CCR5 gene with juvenile rheumatoid arthritis
###end article-title 52
###begin article-title 53
Genetic variation in CCR5 does not predict clinical outcome in inflammatory arthritis
###end article-title 53
###begin article-title 54
Negative association between the chemokine receptor CCR5-Delta32 polymorphism and rheumatoid arthritis: a meta-analysis
###end article-title 54
###begin article-title 55
The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis
###end article-title 55
###begin article-title 56
International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001
###end article-title 56
###begin article-title 57
###xml 148 156 <span type="species:ncbi:9606">patients</span>
The 32-base pair deletion of the chemokine receptor 5 gene (CCR5-Delta32) is not associated with primary sclerosing cholangitis in 363 Scandinavian patients
###end article-title 57
###begin article-title 58
A functional haplotype of the PADI4 gene associated with rheumatoid arthritis in a Japanese population is not associated in a United Kingdom population
###end article-title 58
###begin article-title 59
PADI4 polymorphisms are not associated with rheumatoid arthritis in the Spanish population
###end article-title 59
###begin article-title 60
Replication of putative candidate-gene associations with rheumatoid arthritis in >4,000 samples from North America and Sweden: association of susceptibility with PTPN22, CTLA4, and PADI4
###end article-title 60
###begin article-title 61
Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis
###end article-title 61
###begin article-title 62
Obstacles and opportunities in meta-analysis of genetic association studies
###end article-title 62

